Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy

In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition factor (MET) signaling pathway activation. On the other hand, vascular endoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Oncol
Main Authors: Seki, Nobuhiko, Natsume, Maika, Ochiai, Ryosuke, Haruyama, Terunobu, Ishihara, Masashi, Fukasawa, Yoko, Sakamoto, Takahiko, Tanzawa, Shigeru, Usui, Ryo, Honda, Takeshi, Ota, Shuji, Ichikawa, Yasuko, Watanabe, Kiyotaka
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6381877/
https://ncbi.nlm.nih.gov/pubmed/30792648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000493088
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados